tiprankstipranks
Scinai Immunotherapeutics (SCNI)
NASDAQ:SCNI
Holding SCNI?
Track your performance easily

Scinai Immunotherapeutics (SCNI) Income Statement

305 Followers

Scinai Immunotherapeutics Income Statement

Last quarter (Q ), Scinai Immunotherapeutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q, Scinai Immunotherapeutics's net income was $―. See Scinai Immunotherapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
--$ 7.17M-$ -15.63M-
Cost of Revenue
------
Gross Profit
--$ 7.17M-$ -15.63M-
Operating Expense
$ -7.05M$ 9.71M$ 11.06M$ 10.87M$ 68.15M$ 78.35M
Operating Income
$ 7.05M$ -9.71M$ -11.06M$ -10.87M$ -83.78M$ -78.35M
Net Non Operating Interest Income Expense
$ 209.00K$ 4.14M-$ 2.66M$ 3.84M$ 4.00K
Other Income Expense
-$ -9.00K$ -5.26M$ -12.00K$ -75.48M-
Pretax Income
$ 7.26M$ -6.50M$ -5.80M$ -8.21M$ -4.46M$ -78.35M
Tax Provision
-----$ 30.85M
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ 7.26M$ -6.50M$ -599.60K$ -8.21M$ -4.46M$ -109.19M
Basic EPS
--$ -40.00$ -0.20-$ -3.30
Diluted EPS
--$ -40.00--$ -3.30
Basic Average Shares
$ 1.30B$ 1.56B$ 75.41M$ 56.46M$ 44.33M$ 32.67M
Diluted Average Shares
$ 1.30B$ 1.56B$ 75.41M$ 64.28M$ 44.33M$ 32.67M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ -7.05M$ 9.71M$ 11.06M$ 10.87M$ 68.15M$ 78.35M
Net Income From Continuing And Discontinued Operation
$ 232.00K$ -6.50M$ -599.60K$ -8.21M$ -4.46M$ -109.19M
Normalized Income
$ 3.75M$ -4.78M$ -4.29M---
Interest Expense
$ 6.17M-----
EBIT
$ 13.43M$ -6.49M$ -5.80M$ -8.21M$ -4.46M$ -78.35M
EBITDA
$ 13.56M$ -5.98M$ -5.08M$ -7.59M$ -4.46M$ -78.35M
Currency in USD

Scinai Immunotherapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis